MAP’s vision to accelerate patient access to medicines, devices and diagnostics is at the heart of everything we do.
NHS England was proposing that all primary care prescribing for an acute pain medicine should be halted. This risked adding an extra barrier to effective pain relief for cancer patients. There was limited awareness of the proposed change among the community.
We launched a targeted engagement programme with Parliamentarians and patient groups resulting in many consultation responses which highlighted concerns on proposed changes in prescribing.
Creation and dissemination of key messages to raise awareness of the proposal plus possible impact on cancer patients, particularly those in palliative care.
Our policy and public affairs team created a comprehensive toolkit to support consultation responses.
We established a clear call to action for Parliamentarians which led to Five Parliamentary Questions tabled and at least four personal letters sent from Parliamentarians to either the Minister or to the Chief Executive of NHS England.
NHS England noted a large range of responses to this proposal in its consultation process.
NHS England agreed to exclude palliative care prescribing from its recommendation.
Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281
VAT Group Registration Number:
GB 292 8576 52